| Patent application number | Description | Published |
|---|
| 20090042880 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES - Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R | 02-12-2009 |
| 20090130209 | Novel Pyridazinone Derivatives - Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R | 05-21-2009 |
| 20100105719 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS - The present invention relates to imidazolidinecarboxamide derivatives of the general formula I, | 04-29-2010 |
| 20100152246 | 5-Oxoisoxazoles as inhibitors of lipases and phospholipases - The present invention relates to 5-oxoisoxazole derivatives of the formula I, the pharmaceutically usable salts thereof and the use thereof as medicinal substances. | 06-17-2010 |
| 20100173961 | BENZOOXAZOL-2-ONE DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS - The invention relates to benzooxazol-2-one derivatives of general formula (I) with the meanings indicated in the description, the pharmaceutically usable salts thereof, and the use thereof as medicinal substances. | 07-08-2010 |
| 20100190801 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments. | 07-29-2010 |
| 20100286133 | Diacyl indazole derivatives as lipase and phospholipase inhibitors - The invention relates to diacyl indazole derivatives of general formulae (I) or (II) and to the pharmaceutically acceptable salts thereof: | 11-11-2010 |
| 20110077197 | NOVEL INSULIN DERIVATIVES HAVING AN EXTREMELY DELAYED TIME-ACTION PROFILE - The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4. | 03-31-2011 |
